HEP Retained by Lonza To Sell Hopkinton, MA Facility

By June 26, 2014Press Releases

LONZA HOPKINTON, INC. RETAINS M&A SPECIALIST,

HERITAGE EQUITY PARTNERS

MASSACHUSETS – Lonza Hopkinton, Inc. (“Lonza” or “the Company”) has retained Heritage Equity Partners (“HEP”) to seek a buyer for their state of the art turn-key cGMP-ready biopharmaceutical manufacturing facility.   Lonza, a leading supplier of contract biopharmaceutical development and manufacturing services, based in Switzerland, built out this facility which is ideally suited for microbial fermentation and purification of bulk biopharmaceutical drug substance, or potentially vaccines, cell therapy, oral grade pharmaceuticals or similar products.  The facility is also potentially suitable for Mammalian production, laboratory testing activities, research and development work, nutraceuticals, enzymes, animal health, cosmetics or food processing products.   This is a unique opportunity for a potential buyer in these high tech areas, allowing one to bypass a timely greenfield capital project and enter into this turnkey operation.

The operation is located 27 miles west of Boston in two adjacent 64,000 sq.ft. buildings.  The facility has a demonstrated track record of manufacturing over 500 successful batches of biopharmaceutical products since 1997. Each building has full utilities including WFI and pure steam and extensive GMP clean rooms.  The facility was designed for manufacturing novel protein therapeutics, antibody fragments, vaccines, virus-like particles, cytokines, interferons, growth factors, polysaccharide-proteins conjugates, and recombinant peptides.  There are five production trains suitable to produce antibody fragments, vaccines, polysaccharide-protein conjugates, plasmid DNA, and PEGylated products using microbial fermentation.  The operational components of  the production trains include eight equipped and operation ready manufacturing suites with production scales from 40L (clinical) to 2,800L (commercial) suitable for fermentation and purification.

Hank Waida, a Managing Director at HEP, says that “This is an excellent opportunity to acquire, in place, at a discount of the estimated $200 million replacement cost, a turnkey cGMP operation, eliminating the lengthy process and enormous expense associated with planning, build out, and equipment purchase of a new facility.”

Easton, Maryland – based Heritage Equity Partners, formerly “Equity Partners”, provides investment banking services and has completed in excess of 400 engagements throughout the United States since 1988.